Cellectar Biosciences
CLRBClinical Pipeline
No assets found matching the corporate key (CLRB)
Financial Statements & Analysis
Total Gross Revenue
— — — —
Cost of Revenue / Sales
— — — —
Gross Profit
— — — —
OPERATING EXPENSES
2025-06-302025-09-302025-12-312026-03-31
Research & Development (R&D)
($2.39M) ($2.52M) ($11.50M) ($3.01M)
Selling & Marketing Expense
— — — —
General & Administrative (G&A)
($3.65M) ($2.33M) ($11.48M) ($2.79M)
Operating Income / (Loss)
($6.04M) ($4.85M) ($22.98M) ($5.79M)
NON-OPERATING & FINANCING ITEMS
2025-06-302025-09-302025-12-312026-03-31
Interest Income / Cash Yields
— — — —
Interest & Debt Servicing Expense
— — — —
Other Non-Operating Income / (Expense)
$0.59M $0.41M $1.19M $0.14M
Income Tax Provision / (Benefit)
— — — —
NET INCOME / (NET LOSS)
($5.45M) ($4.44M) ($21.79M) ($5.65M)
ASSETS (CURRENT & FIXED)
2025-06-302025-09-302025-12-312026-03-31
Cash and Cash Equivalents
$11.0M$12.6M$13.2M$8.3M
Short-Term Marketable Investments
// --// --// --// --
Total Liquid Cash Resources
$11.0M$12.6M$13.2M$8.3M
Accounts Receivable, Net
// --// --// --// --
Prepaid Expenses & Other Current Assets
$1.6M$1.1M$0.8M$0.9M
Total Current Assets
$12.6M$13.6M$14.0M$9.3M
Property, Plant and Equipment, Net
$0.6M$0.6M$0.5M$0.3M
Intangibles & Other Non-Current Assets
// --// --// --// --
TOTAL CONSOLIDATED ASSETS
$13.7M$14.6M$15.0M$11.1M
LIABILITIES & STOCKHOLDERS' EQUITY
2025-06-302025-09-302025-12-312026-03-31
Accounts Payable
// --// --$1.4M// --
Accrued Expenses & Clinical Liabilities
// --// --// --// --
Total Current Liabilities
$5.9M$4.9M$4.7M$4.9M
Long-Term Corporate Debt Balances
// --// --// --// --
Deferred Revenue & Collaboration Liabilities
// --// --// --// --
Other Long-Term Obligations
$0.4M$0.3M$0.3M$1.5M
Total Liabilities Block
$6.2M$5.2M$5.1M$6.4M
Total Stockholders' Equity
$6.1M$8.0M$8.5M$3.3M
TOTAL LIABILITIES & EQUITY
$12.3M$13.2M$13.6M$9.7M
HISTORICAL RATIO ANALYSIS
2025-06-302025-09-302025-12-312026-03-31
Current Liquidity Ratio
2.15x 2.77x 2.96x 1.90x
R&D Expenditure Flow
$5.8M$8.3M$11.5M$3.0M
Net Income / (Loss)
($5.45M) ($4.44M) ($21.79M) ($5.65M)
Depreciation & Amortization
$0.11M $0.16M $0.21M —
Stock-Based Compensation
$1.13M $1.70M $2.26M $0.45M
Change in Accounts Receivable
— — — —
Change in Prepaid Assets / Expenses
$0.61M $0.11M ($0.12M) ($0.25M)
Change in Payables & Clinical Accruals
($2.91M) ($3.57M) ($3.16M) $0.30M
Other Operating Source / (Use) Changes
($8.00M) ($12.73M) ($0.52M) $0.30M
Net Cash from Operating Activities
($14.50M) ($18.77M) ($23.12M) ($4.85M)
INVESTING ACTIVITIES
2025-06-302025-09-302025-12-312026-03-31
Capital Expenditures (CapEx)
— — ($0.01M) ($0.00M)
Purchases of Marketable Securities
— — — —
Maturities & Sales of Investments
— — — —
Net Cash from Investing Activities
— — ($0.01M) ($0.00M)
FINANCING ACTIVITIES
2025-06-302025-09-302025-12-312026-03-31
Proceeds from Issuing Debt Instruments
— — — —
Repayments of Debt / Leases
— — — —
Proceeds from Issuing Stock / ATM Options
— — — —
Net Cash from Financing Activities
$2.25M $8.04M $13.03M —
NET CONSOLIDATED CHANGE IN CASH
($12.25M) ($10.73M) ($10.09M) ($4.85M)
Clinical Trials Registry
No active clinical trials detected in data stream.